Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402.
Aged
Aged, 80 and over
Albumins
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Paclitaxel
/ therapeutic use
Platinum
/ therapeutic use
Progression-Free Survival
nab-PTX monotherapy
non-small cell lung cancer
phase I/II trial
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
25
08
2021
received:
02
06
2021
accepted:
26
08
2021
pubmed:
16
9
2021
medline:
2
2
2022
entrez:
15
9
2021
Statut:
ppublish
Résumé
NJLCG1402 was a phase I/II trial investigating biweekly nanoparticle albumin-bound paclitaxel (nab-PTX) in patients with advanced non-small cell lung cancer (NSCLC). The study included patients aged ≥20 years with previously treated NSCLC. Nab-PTX (100-150 mg/m A total of 15 patients received biweekly nab-PTX (100-150 mg/m Biweekly nab-PTX monotherapy was well tolerated and exhibited favorable antitumor activity in patients with previously treated NSCLC.
Sections du résumé
BACKGROUND
NJLCG1402 was a phase I/II trial investigating biweekly nanoparticle albumin-bound paclitaxel (nab-PTX) in patients with advanced non-small cell lung cancer (NSCLC).
METHODS
The study included patients aged ≥20 years with previously treated NSCLC. Nab-PTX (100-150 mg/m
RESULTS
A total of 15 patients received biweekly nab-PTX (100-150 mg/m
CONCLUSIONS
Biweekly nab-PTX monotherapy was well tolerated and exhibited favorable antitumor activity in patients with previously treated NSCLC.
Identifiants
pubmed: 34523232
doi: 10.1111/1759-7714.14149
pmc: PMC8563146
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Platinum
49DFR088MY
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2886-2893Informations de copyright
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Lung Cancer. 2013 Jul;81(1):97-101
pubmed: 23545279
J Thorac Oncol. 2009 Dec;4(12):1544-9
pubmed: 19884862
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Cancer Chemother Pharmacol. 2016 Aug;78(2):383-8
pubmed: 27339149
J Clin Oncol. 2000 Jun;18(12):2354-62
pubmed: 10856094
Medicine (Baltimore). 2017 Dec;96(51):e9320
pubmed: 29390506
Oncotarget. 2017 Sep 20;8(50):87442-87454
pubmed: 29152093
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Clin Lung Cancer. 2012 Jan;13(1):39-43
pubmed: 21890422
Lung Cancer. 2003 Jan;39(1):55-61
pubmed: 12499095
J Clin Oncol. 2008 Feb 1;26(4):639-43
pubmed: 18235124
Med Oncol. 2015 Jun;32(6):498
pubmed: 25944796
N Engl J Med. 2005 Jul 14;353(2):123-32
pubmed: 16014882
J Thorac Oncol. 2021 Sep;16(9):1523-1532
pubmed: 33915251
Clin Cancer Res. 2002 May;8(5):1038-44
pubmed: 12006516
Invest New Drugs. 2018 Oct;36(5):903-910
pubmed: 29846848
Lung Cancer. 2016 Sep;99:41-5
pubmed: 27565912
Clin Cancer Res. 2005 Jun 1;11(11):4136-43
pubmed: 15930349
Oncologist. 2017 Jun;22(6):640-e59
pubmed: 28526722
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Clin Oncol. 2000 May;18(10):2095-103
pubmed: 10811675
Thorac Cancer. 2021 Nov;12(21):2886-2893
pubmed: 34523232
J Clin Oncol. 2012 Jun 10;30(17):2055-62
pubmed: 22547591
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Ann Oncol. 2017 Nov 1;28(11):2698-2706
pubmed: 29045553
J Clin Oncol. 2004 May 1;22(9):1589-97
pubmed: 15117980
Clin Lung Cancer. 2017 Jan;18(1):100-103
pubmed: 28341108